Major pathologic response to neoadjuvant pembrolizumab in advanced melanoma trial exceeds 50%
by SWOG Cancer Research NetworkCredit: CC0 Public DomainIn exploratory analyses of results from the SWOG S1801 trial in patients with stage III-IV resectable melanoma, researchers saw a major patholog
Updated on: April 22,2024
20

Major pathologic response to neoadjuvant pembrolizumab in advanced melanoma trial exceeds 50%
by SWOG Cancer Research NetworkCredit: CC0 Public DomainIn exploratory analyses of results from the SWOG S1801 trial in patients with stage III-IV resectable melanoma, researchers saw a major patholog
Updated on:April 22,2024
20
